NEW DELHI: Drug agency AstraZeneca Pharma India on Sunday mentioned it has acquired import and market permission from the Indian drug regulator for Selumetinib capsules.
The corporate has acquired the import and market permission in Type CT-20 from the Drugs Controller Basic of India for Selumetinib 10 mg & 25 mg capsules, AstraZeneca Pharma India mentioned in a regulatory submitting.
The receipt of this permission paves manner for the launch of Selumetinib 10 mg & 25 mg capsules in India, topic to the receipt of associated statutory approvals and licenses, it added.
Selumetinib 10 mg & 25 mg capsules are indicated for remedy of pediatric sufferers 3 years of age and older with neurofibromatosis kind 1 and who’ve symptomatic, inoperable plexiform neurofibromas, it added.





Source link

Leave a Reply